Some interesting papers being presented. A few tasters, but many...

Some interesting papers being presented. A few tasters, but many more very +ve papers. Enjoy.

ID 38 - Selection between locoregional embolotherapies for hepatic metastases from neuroendocrine tumor:​

Conclusions:​

In patients with small tumor burdens, cTACE may be preferred over DEB-TACE due to equivalent efficacy with lower incidence of biliary complications. DEB-TACE was more efficacious then cTACE and equivalently safe in larger tumor burdens, but TARE demonstrated even greater efficacy.

ID 169 - Frequency of Complete Pathological Necrosis in HCC of Explanted Livers: Radioembolization with Resin vs Drug Eluting Beads with Doxorubicin​

Conclusions:​

RE or DEB-TACE result in a high rate of pathological necrosis. A higher rate CPN was seen in the RE group compared to DEB-TACE with statistical significance. Further prospective studies are needed to validate these findings.

ID - 170 - Radioembolization Super Survivors: Hepatocellular Carcinoma​

With IRB approval, a search of our prospectively acquired database (2003-2016) identified 77 non-surgical HCC patients treated with Y90 and deemed "Super Survivors" (defined as ≥3yrs survivorship after Y90). ​

Conclusions:​

Super survivors have heterogeneous baseline characteristics and advanced age at the time of treatment yet maintained durable OS after radioembolization that is stratified by the extent of underlying liver disease. The implemented technical approach (segmental vs lobar) may be a relevant long-term predictor of OS in super survivors.

ID 171 - Radioembolization vs. Chemoembolization for Unresectable Solitary Hepatocellular Carcinoma ≤3 cm​

Conclusions:​

Preliminary analysis suggests an efficacy benefit of RE compared to TACE in patients with unresectable solitary HCC ≤3 cm. Further analysis to account for significant differences seen in the baseline characteristics of this cohort will allow for more robust conclusions.​

ID 174 - Survival Outcomes Following Radioembolization for Hepatocellular Carcinoma: Results from a 948 Patient Cohort​

Conclusions:​

Radioembolization results in survival outcomes that are affected by the baseline characteristics. Patients with preserved liver function (CP A) within Milan criteria demonstrate improved long term outcomes with a median survival of 67.5 months. This type of analysis using big data permits substratification of patients and identification of those that may benefit maximally from radioembolization.

[COLOR=#4f4f4f]ID 175 - Survival Analysis of Hepatocellular Carcinoma Treated with Radioembolization versus Best Supportive Care: A Surveillance, Epidemiology, and End Results (SEER) Program Study[/COLOR]​

[COLOR=#4f4f4f][B]Results:[/B][/COLOR]​

A total of 12,543 patients in the pooled cohort were included (340 receiving 90Y and 12,203 receiving BSC). The average age was 61 yrs (SD 11.8 months). There were significant differences in the groups in race, stage, tumor grade, extension and AJCC stage. [B]There was significantly better overall survival (OS) in the 90Y group (9 mos, 95% CI 2-3 months) compared to the BSC group (2 mos, 95% CI 2-3 months) with a p<0.0001. Propensity matching generated 127 matched pairs with similar background characteristics in all background variables. Survival advantage for 90Y was maintained with a median survival of 9 mos (95% CI 8-11 months) for 90Y and 4 mos for BSC (95% CI 3-6 months) with a p<0.0001[/B]. On cox regression analysis, age, treatment selection, tumor grade, extension, AJCC stage and tumor size were found as independent prognostic factors for OS.​

[COLOR=#4f4f4f][B]Conclusions:[/B][/COLOR]​

In this propensity-matched population study of advanced HCC, better OS was seen in patients receiving 90Y compared to BSC.​

​

​

​

​